Pub Date : 2026-01-01Epub Date: 2025-10-06DOI: 10.1007/s10096-025-05253-y
Vanishree B, Wilfred Ruban Savariraj, Mohan H V, Jaganatha Rao, Porteen Kannan, Anbazhagan Subbaiyan, Sureshkannan S, Nidhi Sudhakaran P, Nithya Quintoil M, Sivachandiran R, Sivaraman Gopalan Krishnan, Raghavendra G Amachawadi
Acinetobacter baumannii is a multidrug-resistant (MDR) pathogen increasingly detected in livestock and food products, raising concerns about zoonotic transmission. This study characterized A. baumannii isolates from retail meat sources in India, assessing their genomic diversity, antimicrobial resistance (AMR), virulence factors (VFs), and mobile genetic elements (MGEs). Nine A. baumannii isolates from chicken, buffalo, pork, mutton, and prawn were identified via CHROMagar™, biochemical tests, BD Phoenix™ M50, and rpoB PCR. Antibiotic susceptibility was determined using MIC assays. Whole-genome sequencing (WGS) was performed, followed by phylogenetic, resistome, virulome, and mobilome analyses with global animal, avian and meat isolates. All nine isolates exhibited resistance to β-lactams (amoxicillin-clavulanic acid, ampicillin, aztreonam, cefazolin, cefoxitin) but remained susceptible to tetracycline, amikacin, ciprofloxacin, and carbapenems. Genomic analysis revealed 3.67-3.9 Mbp genomes with 27-49 contigs, harboring 17-22 AMR genes per isolate. Global phylogenetic analysis identified two major clades with host- and country-specific clustering (e.g., ST-1512-OCL2-KL9 in Indian retail chicken, ST-25-OCL6-KL14 in French companion animals). Core VFs included biofilm formation (ompA, csuA-E, pgaA-D), iron acquisition (basA-J, bauA-F), and LPS biosynthesis genes. Plasmid prediction identified 242 plasmids (55 conjugative, 32 mobilizable), with 112 carrying AMR genes (AAC, APH, sul2, tet(B)). MGEs (IS, Tn, ICE) were linked to blaOXA-23, blaNDM-1, and aminoglycoside resistance genes. Capsular (KL) and lipooligosaccharide (OCL) loci showed geographic and host-specific distributions (e.g., KL14-OCL6 in France, KL19-OCL1 in UK livestock). Retail meat serves as a reservoir for MDR A. baumannii, with genomic features mirroring clinical strains. The presence of high-risk clones (IC-2, IC-5), carbapenem resistance genes (blaOXA-23, blaNDM-1), and mobilizable AMR plasmids underscores the risk of zoonotic transmission. A One Health approach integrating WGS-based surveillance is critical to mitigate the spread of AMR A. baumannii through food chains.
{"title":"Isolation and whole-genome characterization of multidrug-resistant Acinetobacter baumannii from Indian retail meat: unveiling high-risk clones and zoonotic transmission threats via comparative genomics.","authors":"Vanishree B, Wilfred Ruban Savariraj, Mohan H V, Jaganatha Rao, Porteen Kannan, Anbazhagan Subbaiyan, Sureshkannan S, Nidhi Sudhakaran P, Nithya Quintoil M, Sivachandiran R, Sivaraman Gopalan Krishnan, Raghavendra G Amachawadi","doi":"10.1007/s10096-025-05253-y","DOIUrl":"10.1007/s10096-025-05253-y","url":null,"abstract":"<p><p>Acinetobacter baumannii is a multidrug-resistant (MDR) pathogen increasingly detected in livestock and food products, raising concerns about zoonotic transmission. This study characterized A. baumannii isolates from retail meat sources in India, assessing their genomic diversity, antimicrobial resistance (AMR), virulence factors (VFs), and mobile genetic elements (MGEs). Nine A. baumannii isolates from chicken, buffalo, pork, mutton, and prawn were identified via CHROMagar™, biochemical tests, BD Phoenix™ M50, and rpoB PCR. Antibiotic susceptibility was determined using MIC assays. Whole-genome sequencing (WGS) was performed, followed by phylogenetic, resistome, virulome, and mobilome analyses with global animal, avian and meat isolates. All nine isolates exhibited resistance to β-lactams (amoxicillin-clavulanic acid, ampicillin, aztreonam, cefazolin, cefoxitin) but remained susceptible to tetracycline, amikacin, ciprofloxacin, and carbapenems. Genomic analysis revealed 3.67-3.9 Mbp genomes with 27-49 contigs, harboring 17-22 AMR genes per isolate. Global phylogenetic analysis identified two major clades with host- and country-specific clustering (e.g., ST-1512-OCL2-KL9 in Indian retail chicken, ST-25-OCL6-KL14 in French companion animals). Core VFs included biofilm formation (ompA, csuA-E, pgaA-D), iron acquisition (basA-J, bauA-F), and LPS biosynthesis genes. Plasmid prediction identified 242 plasmids (55 conjugative, 32 mobilizable), with 112 carrying AMR genes (AAC, APH, sul2, tet(B)). MGEs (IS, Tn, ICE) were linked to bla<sub>OXA-23</sub>, bla<sub>NDM-1</sub>, and aminoglycoside resistance genes. Capsular (KL) and lipooligosaccharide (OCL) loci showed geographic and host-specific distributions (e.g., KL14-OCL6 in France, KL19-OCL1 in UK livestock). Retail meat serves as a reservoir for MDR A. baumannii, with genomic features mirroring clinical strains. The presence of high-risk clones (IC-2, IC-5), carbapenem resistance genes (bla<sub>OXA-23</sub>, bla<sub>NDM-1</sub>), and mobilizable AMR plasmids underscores the risk of zoonotic transmission. A One Health approach integrating WGS-based surveillance is critical to mitigate the spread of AMR A. baumannii through food chains.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"157-172"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145231796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-10-04DOI: 10.1007/s10096-025-05284-5
Matilda Dooley, Erik Senneby, Omar Sigurvin Gunnarsson, Anja Carblom, Ann-Cathrine Petersson, Magnus Rasmussen
Purpose: We aimed to investigate the incidence and clinical features of Streptococcus dysgalactiae peripartum infections (SDPI), and to investigate the distribution of emm-types in relation to disease severity and the genetic relatedness of isolates from hospital clusters.
Materials and methods: Patients with growth of S. dysgalactiae in a genital or wound culture, collected between January 2014 and September 2020 at departments for gynecology and obstetrics, were identified. For inclusion, patients had to be pregnant, or given birth, or undergone an abortion within 42 days prior to debut of symptoms. All isolates had previously been emm-typed. A cluster was defined as two or more patients with S. dysgalactiae of the same emm-type admitted to the same hospital within a 30-day period. The cluster isolates were subjected to whole genome sequencing (WGS).
Results: The final study cohort comprised 130 patients. The incidence of S. dysgalactiae postpartum infection was approximately 1 case/1000 births. The patients fulfilled criteria for endometritis (n = 94), postpartum fever (n = 15), wound infection (n = 8) or chorioamnionitis (n = 4). Most patients with endometritis (87%) had onset of symptoms > 48 h post-partum. The most common emm-type was stG62647 (n = 41). Thirteen hospital clusters were identified, of which only three had bacterial isolates that were closely genetically related (0-6 SNP).
Conclusion: Our findings demonstrate that SDPI impact a relatively large number of patients. No patient was critically ill, but the morbidity appeared to be substantial. Hospital outbreaks of SDPI are rare, but when suspected, WGS should be employed to investigate relatedness between isolates.
{"title":"Streptococcus dysgalactiae as a cause of peripartum infections - a population-based cohort study with phylogenetic analysis of hospital clusters.","authors":"Matilda Dooley, Erik Senneby, Omar Sigurvin Gunnarsson, Anja Carblom, Ann-Cathrine Petersson, Magnus Rasmussen","doi":"10.1007/s10096-025-05284-5","DOIUrl":"10.1007/s10096-025-05284-5","url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to investigate the incidence and clinical features of Streptococcus dysgalactiae peripartum infections (SDPI), and to investigate the distribution of emm-types in relation to disease severity and the genetic relatedness of isolates from hospital clusters.</p><p><strong>Materials and methods: </strong>Patients with growth of S. dysgalactiae in a genital or wound culture, collected between January 2014 and September 2020 at departments for gynecology and obstetrics, were identified. For inclusion, patients had to be pregnant, or given birth, or undergone an abortion within 42 days prior to debut of symptoms. All isolates had previously been emm-typed. A cluster was defined as two or more patients with S. dysgalactiae of the same emm-type admitted to the same hospital within a 30-day period. The cluster isolates were subjected to whole genome sequencing (WGS).</p><p><strong>Results: </strong>The final study cohort comprised 130 patients. The incidence of S. dysgalactiae postpartum infection was approximately 1 case/1000 births. The patients fulfilled criteria for endometritis (n = 94), postpartum fever (n = 15), wound infection (n = 8) or chorioamnionitis (n = 4). Most patients with endometritis (87%) had onset of symptoms > 48 h post-partum. The most common emm-type was stG62647 (n = 41). Thirteen hospital clusters were identified, of which only three had bacterial isolates that were closely genetically related (0-6 SNP).</p><p><strong>Conclusion: </strong>Our findings demonstrate that SDPI impact a relatively large number of patients. No patient was critically ill, but the morbidity appeared to be substantial. Hospital outbreaks of SDPI are rare, but when suspected, WGS should be employed to investigate relatedness between isolates.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"135-143"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12872727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-09-20DOI: 10.1007/s10096-025-05250-1
Danni Ma, Fuman Cai, Ting Zhang
Facing challenges in the fields of microbial detection and antimicrobial resistance (AMR) monitoring, the scientific community is opening new research avenues with the help of cutting-edge technologies such as molecular biology, genomics, proteomics, nanotechnology, and bioinformatics. In this review, we comprehensively collate and elaborate on revolutionary detection methods and AMR surveillance strategies that go beyond traditional microbial culture techniques. These innovative methods have not only improved the sensitivity and speed of detection but also broadened our understanding of the microbial world, providing new weapons in the fight against drug-resistant microorganisms. Through the integration and innovation of interdisciplinary approaches, we are gradually constructing a more precise, efficient, and comprehensive new paradigm for microbial detection and AMR testing.
{"title":"Advances in the detection of Drug-Resistant bacteria: current trends and innovations.","authors":"Danni Ma, Fuman Cai, Ting Zhang","doi":"10.1007/s10096-025-05250-1","DOIUrl":"10.1007/s10096-025-05250-1","url":null,"abstract":"<p><p>Facing challenges in the fields of microbial detection and antimicrobial resistance (AMR) monitoring, the scientific community is opening new research avenues with the help of cutting-edge technologies such as molecular biology, genomics, proteomics, nanotechnology, and bioinformatics. In this review, we comprehensively collate and elaborate on revolutionary detection methods and AMR surveillance strategies that go beyond traditional microbial culture techniques. These innovative methods have not only improved the sensitivity and speed of detection but also broadened our understanding of the microbial world, providing new weapons in the fight against drug-resistant microorganisms. Through the integration and innovation of interdisciplinary approaches, we are gradually constructing a more precise, efficient, and comprehensive new paradigm for microbial detection and AMR testing.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"1-17"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-10-13DOI: 10.1007/s10096-025-05306-2
Yanhong Sun, Shilei Dong, Qingxue Zhou
Chlamydia trachomatis (CT) infections in children present distinct diagnostic challenges, ranging from perinatal conjunctivitis and pneumonia to trachoma and, in older children, sexually transmitted infections. This review systematically evaluates contemporary laboratory methods for detecting CT in children. The methods are categorized by their distinct targets, beginning with morphological identification via stains (e.g., Giemsa, immunofluorescence) with or without culture; followed by immunological detection of antigens or antibodies (e.g., ELISA); and finally, molecular analysis using NAATs for DNA or RT-PCR for RNA. Each technique is rigorously examined based on analytical sensitivity, specificity, turnaround time, and technical requirements, with particular emphasis on age-specific specimen selection, sampling logistics, and ethical-legal considerations-especially in cases of suspected abuse. Our analysis confirms that NAATs, particularly real-time PCR, are the first-line diagnostic choice for their superior sensitivity in detecting asymptomatic and low-bacterial-load infections in children. RNA-based detection is highlighted as the preferred method for treatment monitoring due to its ability to differentiate viable pathogens. In resource-limited settings, rapid antigen tests offer a practical screening solution, though require NAAT confirmation. The review also discusses emerging technologies, including isothermal amplification and biosensors, for point-of-care (POC) testing. By synthesizing current evidence with pediatric-specific guidelines from the CDC, WHO, and European health authorities, this review aims to establish an evidence-based framework to guide optimal test selection, improve early detection, and inform public health strategies to reduce the CT disease burden in children.
{"title":"Laboratory detection methods for Chlamydia trachomatis infection in children: a review.","authors":"Yanhong Sun, Shilei Dong, Qingxue Zhou","doi":"10.1007/s10096-025-05306-2","DOIUrl":"10.1007/s10096-025-05306-2","url":null,"abstract":"<p><p>Chlamydia trachomatis (CT) infections in children present distinct diagnostic challenges, ranging from perinatal conjunctivitis and pneumonia to trachoma and, in older children, sexually transmitted infections. This review systematically evaluates contemporary laboratory methods for detecting CT in children. The methods are categorized by their distinct targets, beginning with morphological identification via stains (e.g., Giemsa, immunofluorescence) with or without culture; followed by immunological detection of antigens or antibodies (e.g., ELISA); and finally, molecular analysis using NAATs for DNA or RT-PCR for RNA. Each technique is rigorously examined based on analytical sensitivity, specificity, turnaround time, and technical requirements, with particular emphasis on age-specific specimen selection, sampling logistics, and ethical-legal considerations-especially in cases of suspected abuse. Our analysis confirms that NAATs, particularly real-time PCR, are the first-line diagnostic choice for their superior sensitivity in detecting asymptomatic and low-bacterial-load infections in children. RNA-based detection is highlighted as the preferred method for treatment monitoring due to its ability to differentiate viable pathogens. In resource-limited settings, rapid antigen tests offer a practical screening solution, though require NAAT confirmation. The review also discusses emerging technologies, including isothermal amplification and biosensors, for point-of-care (POC) testing. By synthesizing current evidence with pediatric-specific guidelines from the CDC, WHO, and European health authorities, this review aims to establish an evidence-based framework to guide optimal test selection, improve early detection, and inform public health strategies to reduce the CT disease burden in children.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"41-56"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145279168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-10-17DOI: 10.1007/s10096-025-05307-1
Margarita Dudina, Søren Schou Olesen, Kirstine K Søgaard, Hans Linde Nielsen
Purpose: To examine the incidence, clinical characteristics, and outcomes of pyogenic liver abscess (PLA) in a population-based cohort.
Methods: We conducted a population-based cohort study of patients diagnosed with PLA in the North Denmark Region from 2010 to 2022. Cases were identified using ICD-10 discharge code (K75.0) and/or microbiology samples, followed by medical record review. We estimated incidence rates, 30-day mortality, and used Cox regression to estimate hazard ratios (HRs) for all-cause mortality within 365 days, stratified by clinical and microbiological factors.
Results: We identified 249 patients (56% male) with a median age of 68 years (IQR, 59-77). The mean annual incidence was 3.1 per 100,000 person-years, increasing from 2.9 in 2010 to 4.8 in 2022. The most common symptoms were fever (57%) and abdominal pain (48%). Biliary tract disease was the most frequent source, accounting for 35%, while 31% were cryptogenic. A microbiological diagnosis was established in 171 patients (69%), most often isolating Escherichia coli and Streptococcus anginosus group. Drainage was performed in 73% of cases, and piperacillin/tazobactam was the most used intravenous antibiotic. The 30-day mortality was 5%, rising to 22% at one year. In multivariable analysis, malignancy (HR 3.19, 95% CI: 1.30-7.82) and polymicrobial abscess cultures (HR 4.15, 95% CI: 1.23-14.07) were associated with increased 365-day all-cause mortality. In contrast, drainage, infected cysts, multifocal abscesses, and blood culture positivity were not.
Conclusion: PLA incidence increased over the study period. While short-term mortality was low, one-year mortality was high among patients with malignancy or polymicrobial infection.
{"title":"Pyogenic liver abscess in the North Denmark Region - a population-based cohort study (2010-2022).","authors":"Margarita Dudina, Søren Schou Olesen, Kirstine K Søgaard, Hans Linde Nielsen","doi":"10.1007/s10096-025-05307-1","DOIUrl":"10.1007/s10096-025-05307-1","url":null,"abstract":"<p><strong>Purpose: </strong>To examine the incidence, clinical characteristics, and outcomes of pyogenic liver abscess (PLA) in a population-based cohort.</p><p><strong>Methods: </strong>We conducted a population-based cohort study of patients diagnosed with PLA in the North Denmark Region from 2010 to 2022. Cases were identified using ICD-10 discharge code (K75.0) and/or microbiology samples, followed by medical record review. We estimated incidence rates, 30-day mortality, and used Cox regression to estimate hazard ratios (HRs) for all-cause mortality within 365 days, stratified by clinical and microbiological factors.</p><p><strong>Results: </strong>We identified 249 patients (56% male) with a median age of 68 years (IQR, 59-77). The mean annual incidence was 3.1 per 100,000 person-years, increasing from 2.9 in 2010 to 4.8 in 2022. The most common symptoms were fever (57%) and abdominal pain (48%). Biliary tract disease was the most frequent source, accounting for 35%, while 31% were cryptogenic. A microbiological diagnosis was established in 171 patients (69%), most often isolating Escherichia coli and Streptococcus anginosus group. Drainage was performed in 73% of cases, and piperacillin/tazobactam was the most used intravenous antibiotic. The 30-day mortality was 5%, rising to 22% at one year. In multivariable analysis, malignancy (HR 3.19, 95% CI: 1.30-7.82) and polymicrobial abscess cultures (HR 4.15, 95% CI: 1.23-14.07) were associated with increased 365-day all-cause mortality. In contrast, drainage, infected cysts, multifocal abscesses, and blood culture positivity were not.</p><p><strong>Conclusion: </strong>PLA incidence increased over the study period. While short-term mortality was low, one-year mortality was high among patients with malignancy or polymicrobial infection.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"287-296"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12872774/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145307264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-10-15DOI: 10.1007/s10096-025-05311-5
Meishan Lin, Kangying Wang, Dong Lin
{"title":"Analysis of common respiratory pathogens in children aged 0-5 years with community-acquired pneumonia.","authors":"Meishan Lin, Kangying Wang, Dong Lin","doi":"10.1007/s10096-025-05311-5","DOIUrl":"10.1007/s10096-025-05311-5","url":null,"abstract":"","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"247-260"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145291508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-10-13DOI: 10.1007/s10096-025-05298-z
Anna Olsson, Alexandra Rafeletou, Amanda Åman, Nicolette Athanasiou, Celia García-Rivera, Derek Gerstbrein, Brian Mesich, Logan Patterson, Julia Vahturova, Nicole VanZeeland, Andrea Ricart-Silvestre, Matthew L Faron, Jessica Hoff, Kevin Alby, Marina Ivanova, Juan Carlos Rodríguez Díaz, Cecilia Johansson, Christer Malmberg
Increased antibiotic resistance highlights the need for new, rapid antibiotic susceptibility tests to guide therapy, especially in critical disease such as bloodstream infections and sepsis. This study investigates a new ultra-rapid AST system in multiple clinical laboratories, with respect to accuracy, speed and turnaround time in comparison to commonly used AST systems. The QuickMIC system is compared to the commonly used automated AST systems BD Phoenix™ (BD, USA), MicroScan WalkAway plus (Beckman Coulter, USA) and VITEK® 2 (bioMérieux, France) by concurrent testing of incoming positive blood-cultures with Gram-negative bacteria in four clinical laboratories located in the EU and USA, on the basis of agreement of results, time-to-result (TTR, analysis time) and turnaround time (TAT, time from blood culture positivity or blood culture processing to actionable result). A total of 155 patient samples were included, totaling 10 species of Gram-negative bacteria. The overall EA and CA between QuickMIC® GN and each routine AST system was > 95%, while overall bias was within the acceptable range of ± 30%. QuickMIC time-to-result was on average 3 h and 4 min, compared to 9-19 h for the routine systems. The average QuickMIC system turnaround-time ranged from 10 to 11 h 30 min, compared to 22-45 h for the routine systems. The QuickMIC system represents a promising rapid AST technology with potential to reduce time-to-result and overall turnaround-time of clinically actionable AST results compared with the most common routinely used automated AST methods, while maintaining good accuracy and quality of results.
抗生素耐药性的增加突出表明需要新的、快速的抗生素敏感性试验来指导治疗,特别是在血液感染和败血症等危重疾病中。本研究在多个临床实验室研究了一种新的超快速AST系统,与常用的AST系统相比,在准确性、速度和周转时间方面。QuickMIC系统与常用的自动化AST系统BD Phoenix™(BD,美国)、MicroScan WalkAway plus (Beckman Coulter,美国)和VITEK®2 (biomacrieux,法国)进行比较,通过在位于欧盟和美国的四个临床实验室同时检测传入的革兰氏阴性细菌阳性血培养物,基于结果一致性、结果到时间(TTR,分析时间)和周转时间(TAT)。从血培养阳性或血培养处理到可操作结果的时间)。共纳入患者标本155份,革兰氏阴性菌10种。QuickMIC®GN与每个常规AST系统之间的总EA和CA为bb0.95%,而总体偏差在±30%的可接受范围内。与常规系统的9-19小时相比,快速mic到结果的平均时间为3小时4分钟。QuickMIC系统的平均周转时间为10至11小时30分钟,而常规系统的周转时间为22至45小时。QuickMIC系统代表了一种很有前途的快速AST技术,与最常用的常规自动化AST方法相比,它有可能缩短临床可操作AST结果的时间和总体周转时间,同时保持良好的准确性和结果质量。
{"title":"Multicenter evaluation of the QuickMIC<sup>®</sup> rapid AST system in clinical practice: impact on turnaround time compared to routine AST systems.","authors":"Anna Olsson, Alexandra Rafeletou, Amanda Åman, Nicolette Athanasiou, Celia García-Rivera, Derek Gerstbrein, Brian Mesich, Logan Patterson, Julia Vahturova, Nicole VanZeeland, Andrea Ricart-Silvestre, Matthew L Faron, Jessica Hoff, Kevin Alby, Marina Ivanova, Juan Carlos Rodríguez Díaz, Cecilia Johansson, Christer Malmberg","doi":"10.1007/s10096-025-05298-z","DOIUrl":"10.1007/s10096-025-05298-z","url":null,"abstract":"<p><p>Increased antibiotic resistance highlights the need for new, rapid antibiotic susceptibility tests to guide therapy, especially in critical disease such as bloodstream infections and sepsis. This study investigates a new ultra-rapid AST system in multiple clinical laboratories, with respect to accuracy, speed and turnaround time in comparison to commonly used AST systems. The QuickMIC system is compared to the commonly used automated AST systems BD Phoenix™ (BD, USA), MicroScan WalkAway plus (Beckman Coulter, USA) and VITEK<sup>®</sup> 2 (bioMérieux, France) by concurrent testing of incoming positive blood-cultures with Gram-negative bacteria in four clinical laboratories located in the EU and USA, on the basis of agreement of results, time-to-result (TTR, analysis time) and turnaround time (TAT, time from blood culture positivity or blood culture processing to actionable result). A total of 155 patient samples were included, totaling 10 species of Gram-negative bacteria. The overall EA and CA between QuickMIC<sup>®</sup> GN and each routine AST system was > 95%, while overall bias was within the acceptable range of ± 30%. QuickMIC time-to-result was on average 3 h and 4 min, compared to 9-19 h for the routine systems. The average QuickMIC system turnaround-time ranged from 10 to 11 h 30 min, compared to 22-45 h for the routine systems. The QuickMIC system represents a promising rapid AST technology with potential to reduce time-to-result and overall turnaround-time of clinically actionable AST results compared with the most common routinely used automated AST methods, while maintaining good accuracy and quality of results.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"185-196"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12872699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145279161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-30DOI: 10.1007/s10096-025-05396-y
Chen Peng, Jie Hou, Xin Li, Ao Deng, Ze-Hao Wang, Xue-An Wang, Bin Yang, Li-Sha Luo
{"title":"Clinical application of MALDI-TOF MS for direct and rapid pathogen identification: a comprehensive review focusing on bloodstream infections and sterile body fluids.","authors":"Chen Peng, Jie Hou, Xin Li, Ao Deng, Ze-Hao Wang, Xue-An Wang, Bin Yang, Li-Sha Luo","doi":"10.1007/s10096-025-05396-y","DOIUrl":"https://doi.org/10.1007/s10096-025-05396-y","url":null,"abstract":"","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145854951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-29DOI: 10.1007/s10096-025-05392-2
Suyun Yong, Mengjie Yang, Mi Zhou
In recent years, the use of antibiotics in pediatric patients has received widespread. Tosufloxacin is a quinolone antimicrobial used to treat pneumonia, otitis media, cholera, and anthrax. Guidelines have recommended that quinolone antimicrobials can be used as alternatives for the treatment of bacterial infections in children. However, due to the potential adverse effects on bones and joints, the clinical application of fluoroquinolones requires further evaluation. This article reviewed the latest clinical evidence on the efficacy and safety of tosufloxacin for treating bacterial infections in children. Pharmacokinetic results suggested that drug clearance and volume of distribution were significantly correlated with body weight in children, and the higher the AUC and Cmax, the higher the incidence of adverse drug effects. The efficacy results suggest that for Macrolide-resistant Mycoplasma pneumoniae (MRMP), tosufloxacin may have better efficacy compared to macrolide antibiotics, with minocycline being more efficacious than tosufloxacin. Tosufloxacin has good efficacy in the treatment of otitis media infections in children as well as children under 2 years of age, and it can be used as a second-line choice for children with persistent otitis media. The safety results suggest that the most important adverse effect of tosufloxacin is diarrhea, and there are almost no joint-related adverse effects. The rate of adverse effects of 6 mg/kg tosufloxacin is higher than 4 mg/kg group. Tosufloxacin may be safe and effective in children pneumonia and otitis media, but is less effective than minocycline in MRMP.
{"title":"Efficacy and safety review of tosufloxacin in the treatment of bacterial infection in children.","authors":"Suyun Yong, Mengjie Yang, Mi Zhou","doi":"10.1007/s10096-025-05392-2","DOIUrl":"https://doi.org/10.1007/s10096-025-05392-2","url":null,"abstract":"<p><p>In recent years, the use of antibiotics in pediatric patients has received widespread. Tosufloxacin is a quinolone antimicrobial used to treat pneumonia, otitis media, cholera, and anthrax. Guidelines have recommended that quinolone antimicrobials can be used as alternatives for the treatment of bacterial infections in children. However, due to the potential adverse effects on bones and joints, the clinical application of fluoroquinolones requires further evaluation. This article reviewed the latest clinical evidence on the efficacy and safety of tosufloxacin for treating bacterial infections in children. Pharmacokinetic results suggested that drug clearance and volume of distribution were significantly correlated with body weight in children, and the higher the AUC and C<sub>max</sub>, the higher the incidence of adverse drug effects. The efficacy results suggest that for Macrolide-resistant Mycoplasma pneumoniae (MRMP), tosufloxacin may have better efficacy compared to macrolide antibiotics, with minocycline being more efficacious than tosufloxacin. Tosufloxacin has good efficacy in the treatment of otitis media infections in children as well as children under 2 years of age, and it can be used as a second-line choice for children with persistent otitis media. The safety results suggest that the most important adverse effect of tosufloxacin is diarrhea, and there are almost no joint-related adverse effects. The rate of adverse effects of 6 mg/kg tosufloxacin is higher than 4 mg/kg group. Tosufloxacin may be safe and effective in children pneumonia and otitis media, but is less effective than minocycline in MRMP.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145854966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}